Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CRM 107

Known as: CRM-107, CRM107 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Transferrin (Tf) conjugates of CRM107 are currently being tested in clinical trials for treatment of malignant gliomas. However… Expand
Review
2006
Review
2006
Despite the progress of the bioinformatics approach to characterize cell-surface antigens and receptors on tumor cells, it… Expand
  • figure 1
  • figure 2
  • figure 3
1998
1998
Previously a mathematical model was proposed that quantitatively related protein synthesis inhibition kinetics of antitransferrin… Expand
1997
1997
Bispecific antibodies were designed to deliver a reversibly bound ligand into target cells and then spontaneously release it upon… Expand
  • table I
  • table II
  • figure 1
  • table III
  • table V
Highly Cited
1994
Highly Cited
1994
Targeted protein toxins are a new class of reagents with the potential for great tumor selectivity and cytotoxic potency. Two… Expand
  • figure 1
  • figure 3
  • figure 4
1994
1994
We have evaluated the sensitivity to immunotoxins (IT) of monolayer and of 200‐250 μM multicellular tumor spheroid (MTS) cultures… Expand
1990
1990
CRM107 (crossreacting material 107), a double point mutant of diphtheria toxin that lacks receptor-binding activity, specifically… Expand
Highly Cited
1987
Highly Cited
1987
Monoclonal antibodies linked to toxic proteins (immunotoxins) can selectively kill some tumor cells in vitro and in vivo. However… Expand